Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Warns Of Side Effects For Two More Influenza Drugs

This article was originally published in PharmAsia News

Executive Summary

Besides Tamiflu, whose side effects had been previously cautioned, Japan is calling attention to the occurrence of abnormal behaviors in minors taking influenza treatments GlaxoSmithKline's Relenza (zanamivir) and amantadine. Japan's Ministry of Health, Labor and Welfare has received reports of neuropsychiatric events, including patients jumping out of balconies. On Jan. 29, MHLW revised the drugs' package inserts and called physicians' attentions to these side effects. MHLW asked for parental monitoring for at least two days after a minor takes the flu drugs. (Click here for more-Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts